



Universiteit
Leiden
The Netherlands

Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor harboring heterogeneous KIT/PDGFR α mutations in the phase III INVICTUS study

Bauer, S.; Heinrich, M.C.; George, S.; Zalcborg, J.R.; Serrano, C.; Gelderblom, H.; ... ; Schoffski, P.

Citation

Bauer, S., Heinrich, M. C., George, S., Zalcborg, J. R., Serrano, C., Gelderblom, H., ... Schoffski, P. (2021). Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor harboring heterogeneous KIT/PDGFR α mutations in the phase III INVICTUS study. *Clinical Cancer Research*, 27(23), 6333-6342. doi:10.1158/1078-0432.CCR-21-1864

Version: Publisher's Version

License: [Creative Commons CC BY-NC-ND 4.0 license](https://creativecommons.org/licenses/by-nc-nd/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3276569>

Note: To cite this publication please use the final published version (if applicable).

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous *KIT/PDGFR*A Mutations in the Phase III INVICTUS Study



Sebastian Bauer^{1,2}, Michael C. Heinrich^{3,4}, Suzanne George⁵, John R. Zalberg⁶, César Serrano⁷, Hans Gelderblom⁸, Robin L. Jones⁹, Steven Attia¹⁰, Gina D'Amato¹¹, Ping Chi¹², Peter Reichardt¹³, Julie Meade¹⁴, Ying Su¹⁴, Rodrigo Ruiz-Soto¹⁴, Jean-Yves Blay¹⁵, Margaret von Mehren¹⁶, and Patrick Schöffski¹⁷

ABSTRACT

Purpose: Most patients with gastrointestinal stromal tumor (GIST) have activating mutations in *KIT/PDGFR*A and are initially responsive to tyrosine kinase inhibitors (TKI). The acquisition of secondary mutations leads to refractory/relapsed disease. This study reports the results of an analysis from the phase III INVICTUS study (NCT03353753) characterizing the genomic heterogeneity of tumors from patients with advanced GIST and evaluating ripretinib efficacy across *KIT/PDGFR*A mutation subgroups.

Patients and Methods: Tumor tissue and liquid biopsy samples that captured circulating tumor DNA were collected prior to study enrollment and sequenced using next-generation sequencing. Subgroups were determined by *KIT/PDGFR*A mutations and correlation of clinical outcomes and *KIT/PDGFR*A mutational status was assessed.

Results: Overall, 129 patients enrolled (ripertinib 150 mg once daily, $n = 85$; placebo, $n = 44$). The most common primary

mutation subgroup detected by combined tissue and liquid biopsies were in *KIT* exon 11 (ripertinib, 61.2%; placebo, 77.3%) and *KIT* exon 9 (ripertinib, 18.8%; placebo, 15.9%). Patients receiving ripertinib demonstrated progression-free survival (PFS) benefit versus placebo regardless of mutation status (HR 0.16) and in all assessed subgroups in Kaplan–Meier PFS analysis (exon 11, $P < 0.0001$; exon 9, $P = 0.0023$; exon 13, $P < 0.0001$; exon 17, $P < 0.0001$). Among patients with wild-type *KIT/PDGFR*A by tumor tissue, PFS ranged from 2 to 23 months for ripertinib versus 0.9 to 10.1 months for placebo.

Conclusions: Ripertinib provided clinically meaningful activity across mutation subgroups in patients with advanced GIST, demonstrating that ripertinib inhibits a broad range of *KIT/PDGFR*A mutations in patients with advanced GIST who were previously treated with three or more TKIs.

Introduction

Gastrointestinal stromal tumors (GIST) are the most common sarcomas of the digestive tract (annual incidence 10–15 per million individuals) and typically occur in the stomach and small intestine, but can arise anywhere in the gastrointestinal tract (1–3). Most GISTs have activating mutations either in receptor tyrosine kinase: *KIT* (approximately 69%–83% of all GISTs) or platelet-derived growth factor receptor α (*PDGFR*A; approximately 5%–10% of all GISTs; refs. 4–6). Approximately 15% of GISTs lack a *KIT* or *PDGFR*A mutation and are historically classified as *KIT/PDGFR*A wild-type (WT; ref. 6); these

tumors are also referred to as non-*KIT*/non-*PDGFR*A-mutant GIST, as they usually harbor other known oncogenic mutations [proto-oncogene B-Raf (BRAF), neurofibromatosis type-1 (NF1), succinate dehydrogenase deficiency (SDHX); refs. 7, 8]. *KIT/PDGFR*A are dual switch-containing kinases (9, 10). These switch mechanisms regulate cellular *KIT/PDGFR*A conformations and catalytic activities (9). Primary mutations in the *KIT* gene are most commonly found in the juxtamembrane domain inhibitory switch (exon 11, approximately 70%) or the extracellular domain (exon 9, approximately 10%; ref. 11). Mutations in the *KIT* switch pocket adjacent to the ATP-binding pocket (exon 13, approximately 1%) and the *KIT* activation switch

¹Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany. ²German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany. ³VA Portland Veterans Health Care System, Portland, Oregon. ⁴OHSU Knight Cancer Institute, Portland, Oregon. ⁵Dana-Farber Cancer Institute, Boston, Massachusetts. ⁶Monash University School of Public Health and Preventive Medicine and Alfred Health, Melbourne, Victoria, Australia. ⁷Vall d'Hebron Institute of Oncology, Barcelona, Spain. ⁸Leiden University Medical Center, Leiden, the Netherlands. ⁹Royal Marsden and Institute of Cancer Research, London, United Kingdom. ¹⁰Mayo Clinic, Jacksonville, Florida. ¹¹Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida. ¹²Memorial Sloan Kettering Cancer Center, New York, New York. ¹³Sarcoma Center Berlin-Brandenburg, Helios Klinikum Berlin-Buch, Berlin, Germany. ¹⁴Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts. ¹⁵Centre Léon Bérard, Lyon, France. ¹⁶Fox Chase Cancer Center, Temple Health, Philadelphia, Pennsylvania. ¹⁷University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

S. Bauer and M.C. Heinrich are the co-first authors of this article.

Corresponding Author: Sebastian Bauer, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen Hufelandstraße 55, Essen D-45147, Germany. Phone: 4902-0172-32112; Fax: 4902-0172-35996; E-mail: Sebastian.Bauer@uk-essen.de

Clin Cancer Res 2021;27:6333–42

doi: 10.1158/1078-0432.CCR-21-1864

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 International (CC BY-NC-ND).

©2021 The Authors; Published by the American Association for Cancer Research

Translational Relevance

*KIT/PDGFR*A mutations are early oncogenic events in gastrointestinal stromal tumors (GIST) and are key oncogenic metastatic drivers. Clonal evolution of mutations within multiple exons that encode the functional domains of tyrosine kinase receptors have been observed leading to both intra- and intertumor mutational heterogeneity, representing a major mechanism of resistance to existing tyrosine kinase inhibitors (TKI). Here we describe the genomic landscape of *KIT*-related resistance based on an exploratory analysis from INVICTUS. This study investigated *KIT/PDGFR*A mutations using both tumor tissue and liquid biopsies in patients with advanced GIST who were previously treated with at least imatinib, sunitinib, and regorafenib. This is the largest study to reflect the spectrum and extent of mutational heterogeneity in pretreated GIST, underscoring the broad inhibitory activity of ripretinib in this treatment line.

(exon 17, approximately 1%) are less frequent (11). The most common *PDGFR*A primary mutations occur in the activation switch (exon 18, approximately 6%; ref. 11). These mutations in the conformation-controlling switch mechanism, regardless of location, disrupt the auto-inhibited forms of *KIT* and *PDGFR*A kinases and cause constitutive, ligand-independent kinase activity and signaling, ultimately leading to tumor growth and metastasis (12–14).

The current treatment algorithm for patients with advanced, inoperable GIST includes the sequential use of tyrosine kinase inhibitors (TKI) such as imatinib, sunitinib, and regorafenib, which are approved first-, second-, and third-line treatments, respectively (15, 16). These established treatments target the “switch-off” inactive conformation of the kinase by competitively binding to the ATP-binding site (17–19). In particular, some specific *PDGFR*A mutations, mostly the exon 18 D842V substitution mutation, are highly resistant to imatinib treatment. Patients with these mutations may receive the recently approved TKI avapritinib as first-line treatment, as it is approved for patients with unresectable or metastatic GIST that have a *PDGFR*A exon 18 mutation (4, 20, 21).

Secondary mutations typically arise during treatment and can confer resistance to the therapeutic agent. Specifically, secondary *KIT* mutations involving the switch pocket adjacent to the ATP-binding site (exons 13 and 14) or the activation switch (exons 17 and 18) can directly hinder binding of imatinib or stabilize *KIT* oncoprotein in the active conformation (22). These resistance mutations develop within switch domains, driving *KIT/PDGFR*A to an active state. Sunitinib and regorafenib inhibit some resistance mutations, but neither cover the full spectrum of mutations (23–25). Moreover, patients frequently develop separate resistance clones that harbor different resistance mutations, leading to relatively short disease control in second- and third-line treatments for GIST (23–27).

Ripretinib was approved by the FDA in May 2020 for the treatment of adult patients with advanced GIST who received prior treatment with three or more kinase inhibitors, including imatinib (28). In contrast to the mechanism of action of the first three lines of therapy, ripretinib is a switch-control TKI that broadly inhibits *KIT* and *PDGFR*A kinase signaling through a dual mechanism of action (9, 29). Designed to bind to both the switch pocket and the activation switch to lock the kinase in the inactive state, ripretinib prevents downstream

signaling and cell proliferation and provides broad inhibition of *KIT* and *PDGFR*A kinase activity brought on by both primary mutations and secondary mutations that lead to drug-resistant GIST (29). In the phase III INVICTUS study (NCT03353753), patients receiving ripretinib had a statistically significantly longer median progression-free survival (mPFS; 6.3 months) compared with patients receiving placebo (1.0 month; ref. 29).

Tumor tissue biopsy is the traditional gold standard of genotyping in patients with GIST. However, due to the invasive procedures that carry the risk of complications and the time-consuming nature of acquiring tumor tissue biopsies, liquid biopsy that captures circulating tumor DNA (ctDNA) has been used in research in recent years and has demonstrated feasibility and accuracy in detecting *KIT/PDGFR*A mutations in patients with GIST (30–32).

The objectives of this study were to demonstrate the utility of tissue and liquid biopsy in detecting *KIT/PDGFR*A mutations in patients with advanced GIST, characterize the genomic heterogeneity of tumors from patients with advanced GIST enrolled in the INVICTUS trial, and correlate the clinical benefit of ripretinib with baseline mutations.

Patients and Methods

Patient population

The study enrolled patients aged 18 years or older with diagnosed GIST and at least one measurable lesion according to modified Response Evaluation Criteria in Solid Tumors version 1.1 (mRECIST 1.1). Patients who had progressive disease on or documented intolerance to at least imatinib, sunitinib, and regorafenib and an Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 were included. Patients were excluded from the study if they underwent any anticancer therapy within 14 days of starting the study, had uncontrolled hypertension, or had a left ventricular ejection fraction less than 50% at screening. Full inclusion and exclusion criteria can be found in the Supplementary data and have been previously described (29).

Study design and treatment

INVICTUS is an international, multicenter, randomized, double-blind, placebo-controlled phase III trial in 129 patients who received at least three prior anticancer therapies for advanced GIST. Patients were randomized 2:1 to receive ripretinib 150 mg once daily or placebo until disease progression, as determined by blinded independent central review using mRECIST criteria. Randomization was stratified by number of prior anticancer therapies (3 or ≥ 4) and ECOG score (0 vs. 1 or 2), but not by *KIT/PDGFR*A mutation status. The study design and patient disposition for this trial has been published previously (29). This study was conducted in accordance with the Declaration of Helsinki and the International Council for Harmonization Guidelines for Good Clinical Practice. All patients were capable of understanding and complying with the protocol and provided informed written consent to participate in the study. The protocol, protocol amendments, and informed consent documents were approved by the institutional review board or ethics committee at each site before beginning the study.

Outcomes

The primary efficacy outcome for the INVICTUS trial was progression-free survival (PFS). Characterization of mutational status and retrospective correlation between baseline mutation subgroups and efficacy were exploratory outcomes. PFS was assessed for each baseline

mutational subgroup, detected by combining results from the tissue and liquid biopsies.

Sample collection and sequencing analytics

Fresh tumor tissue samples were collected during screening prior to beginning the study drug (baseline). Archival tumor tissue samples could be used as long as no anticancer therapy was administered after the sample was collected. Additional tumor tissue samples may have been collected during the course of the trial (while on study drug) to be used for further molecular testing. However, the data presented here reflect only biopsy samples collected prior to ripretinib treatment. Tumor tissue specimens were analyzed using a next-generation sequencing (NGS), FDA-approved 324-gene assay, FoundationOne (Foundation Medicine, Inc.). Mutations reported in this manuscript are categorized as known or likely cancer-driving alterations and genomic signatures by the assay (33).

Liquid biopsy samples (plasma ctDNA) were collected at cycle 1 day 1 prior to the first dose of study drug (baseline), at the start of every other 28-day cycle, and at the end of treatment. Samples were analyzed via an NGS 73-gene FDA-approved liquid biopsy assay, Guardant360 (Guardant Health, Inc.). This assay reports mutations in a panel of genes that are frequently mutated in cancer and align with the mutations reported by the FoundationOne assay (34). All variants reported by the assay are $\geq 0.02\%$ mutant allele frequency.

Data analysis

Analysis was conducted for the entire intent-to-treat population ($N = 129$) until data cutoff (March 9, 2020). Continuous variables were summarized using descriptive statistics while categorical variables were summarized using frequencies and proportions. Time-to-event data were summarized via Kaplan–Meier methodology with associated two-sided 95% confidence intervals (CI). A two-sided stratified log–rank test (0.05 significance level) was used to evaluate treatment difference. HRs were obtained using a Cox regression analysis adjusted for covariates and the 95% CIs were

obtained using the Wald method. PFS was analyzed only during the double-blind treatment period.

Primary mutation subgroups are presented as detected in tissue, liquid, and combined biopsies. *KIT* exon 9, *KIT* exon 11, or *PDGFRA* mutations were deemed as primary mutations. Any *KIT* mutations detected in addition to primary *KIT* exon 9 or *KIT* exon 11 in a patient were considered secondary mutations. In the absence of a *KIT* exon 9/*KIT* exon 11 mutation, patients were categorized as “other” *KIT* primary subgroup.

Results

Primary mutation subgroups detected in baseline tissue, liquid, and combined biopsies

A total of 129 patients were randomized to either the ripretinib group ($n = 85$) or the placebo arm ($n = 44$). Patient demographics and clinical characteristics were published previously (29). Overall, 128 tumor samples were collected (Fig. 1): 119 during the screening period and 9 prior to study screening. Optional posttreatment tumor tissue samples were collected in only 2 patients and were not analyzed for this manuscript. Most tissue samples were obtained from metastatic lesions. Tissue biopsy detected a single *KIT* mutation in 34 patients, 2 *KIT* mutations in 49 patients, and ≥ 3 *KIT* mutations in 16 patients. The most common primary mutation subgroup in either treatment arm detected in tissue biopsy was in *KIT* exon 11 (ripretinib, 55.3% of tumors, $n = 47$; placebo, 63.6%, $n = 28$) followed by *KIT* exon 9 (ripretinib, 16.5%, $n = 14$; placebo, 13.6%, $n = 6$; Table 1). Only 3 patients (2.34%), all in the ripretinib arm, had a single *PDGFRA* mutation (all exon 18, non-D842V); 10 patients (7.75%; 7 in the ripretinib arm and 3 in the placebo arm) were *KIT*/*PDGFRA* WT (Table 1). A total of 16 tissue biopsy samples failed sequencing, mostly due to low tumor content (Fig. 1).

Liquid biopsy detected a single *KIT* mutation in 25 patients, while 28 patients had 2 *KIT* mutations and 37 patients had ≥ 3 *KIT* mutations. Similar to tissue biopsy, *KIT* exon 11 mutations were the most




Figure 1.

Flow chart of patient biopsies and mutational status. On average, 1.85 *KIT*/*PDGFRA* mutations were detected in each tissue biopsy, while 2.61 *KIT*/*PDGFRA* mutations were detected in each liquid biopsy. *PDGFRA*, platelet-derived growth factor alpha; WT, wild-type.

Table 1. Primary mutation subgroups detected in baseline tissue, liquid, and combined biopsies.

	Ripretinib (n = 85)	Placebo (n = 44)	Total (N = 129)
Baseline tissue biopsy			
Detected mutation, n (%)			
<i>KIT</i> exon 11	47 (55.3)	28 (63.6)	75 (58.1)
<i>KIT</i> exon 9	14 (16.5)	6 (13.6)	20 (15.5)
Not available/not done ^a	12 (14.1)	5 (11.4)	17 (13.2)
Other	12 (14.1)	5 (11.4)	17 (13.2)
<i>KIT/PDGFR</i> A WT	7 (8.24)	3 (6.81)	10 (7.75)
<i>PDGFR</i> A ^b	3 (3.53)	0	3 (2.34)
<i>KIT</i> other exon ^c	2 (2.35)	2 (4.55)	4 (3.10)
Baseline liquid biopsy			
Detected mutation, n (%)			
<i>KIT</i> exon 11 ^d	38 (44.7)	28 (63.6)	66 (51.2)
<i>KIT</i> exon 9 ^d	12 (14.1)	7 (15.9)	19 (14.7)
Not available/not done ^a	6 (7.06)	2 (4.55)	8 (6.20)
Other	29 (34.1)	8 (18.2)	37 (28.7)
<i>KIT/PDGFR</i> A, liquid biopsy negative	22 (25.9)	6 (13.6)	28 (21.7)
<i>PDGFR</i> A ^b	3 (3.53)	0	3 (2.33)
<i>KIT</i> other exon ^c	4 (4.71)	2 (4.55)	6 (4.65)
Baseline combined biopsies			
Detected mutation, n (%)			
<i>KIT</i> exon 11 ^d	52 (61.2)	34 (77.3)	86 (66.7)
<i>KIT</i> exon 9 ^d	16 (18.8)	7 (15.9)	23 (17.8)
Not available/not done ^a	5 (5.88)	0	5 (3.88)
Other	12 (14.1)	4 (9.09)	16 (12.4)
<i>KIT/PDGFR</i> A, liquid biopsy negative	6 (7.06)	3 (6.82)	9 (6.98)
<i>PDGFR</i> A ^b	3 (3.53)	0	3 (2.33)
<i>KIT</i> other exon ^c	3 (3.53)	1 (2.27)	4 (3.10)

^aIncludes patients who failed sequencing due to low tumor content and patients with no specimen.

^bAll patients with *PDGFR*A mutations had exon 18 non-D842V mutations.

^c*KIT* other exon includes any mutation in a *KIT* exon that is not 9 or 11.

^d*KIT* exon 9 + 11 mutation was detected via liquid biopsy in 1 patient receiving placebo and was counted in both groups.

common mutations detected in liquid biopsy (ripresinib, 44.7%, $n = 38$; placebo, 63.6%, $n = 28$) followed by *KIT* exon 9 (ripresinib, 14.1%, $n = 12$; placebo, 15.9%, $n = 7$; **Table 1**). Liquid biopsy detected the same 3 patients in the ripresinib arm with *PDGFR*A mutations (**Table 1**). Liquid biopsy detected primary *KIT/PDGFR*A mutations in 94 patients, while 28 patients were *KIT/PDGFR*A liquid biopsy negative (22 in the ripresinib arm and 6 in the placebo arm; **Table 1**). Only 1 liquid biopsy sample failed sequencing (**Fig. 1**). Among the patients ($n = 80$) with detectable *KIT/PDGFR*A mutations in both tissue and liquid biopsies, the concordance rate of primary mutation was 93.75% ($n = 75$). Consequently, the combination of both technologies (tissue and liquid biopsies) allowed for greater detection of mutations (27 patients had 1 *KIT* mutation, 36 patients had 2 *KIT* mutations, and 49 patients had ≥ 3 *KIT* mutations) and there were fewer samples deemed as not evaluable or not done (tissue biopsy, $n = 17$; liquid biopsy, $n = 8$; combined biopsy, $n = 5$; **Table 1**).

Baseline *KIT* mutations detected outside exons 9 or 11

KIT mutations were detected in both tissue and liquid biopsy outside of exons 9 and 11 in the switch pocket adjacent to the ATP-binding pocket (exons 13 and 14) and the activation switch (exons 17 and 18). Exon 17 and exon 13 mutation commonly coexist with exon 9 or exon 11 mutations (**Fig. 2**). Five different mutations were found in exons 13/14 via tissue biopsy compared with 12 different mutations with liquid biopsy. Fifteen different mutations were found in exons 17/18 via tissue biopsy compared with 26 different mutations with liquid biopsy. When the data were merged, liquid biopsy detected

most of the mutations found in tissue biopsy in addition to several unique mutations. Tissue biopsy only detected four mutations that were not detected in liquid biopsy: two K642Q substitutions in exon 13 and two D820E substitutions in exon 17 (**Fig. 2**). The most common mutations detected by both technologies were V654A substitutions in exon 13 ($n = 23$), N822K substitutions in exon 17 ($n = 14$), and Y823D substitutions in exon 17 ($n = 12$; **Fig. 2**).

Efficacy using baseline combined tumor and liquid biopsy data

Efficacy results in the INVICTUS trial were explored by mutation subgroup using combined tissue and liquid biopsy data. Patients were grouped into 4 subsets based on results of both technologies: any *KIT* exon 9, any *KIT* exon 11, any *KIT* exon 13, and any *KIT* exon 17. Patients were included in multiple groups if they had mutations in more than one exon (i.e., a patient that has a tumor with *KIT* exon 11 and exon 17 mutations would fall into both the “any *KIT* exon 11 group” and the “any *KIT* exon 17 group”). Patients receiving ripresinib showed PFS benefit over placebo regardless of mutation status (HR 0.16, 95% CI, 0.10–0.27) and in all assessed subgroups in Kaplan–Meier PFS analysis (exon 11, $P < 0.0001$; exon 9, $P = 0.0023$; exon 13, $P < 0.0001$; exon 17, $P < 0.0001$; **Fig. 3**). Moreover, the calculated HRs for each subgroup favored ripresinib treatment over placebo (any *KIT* exon 11: HR 0.13, 95% CI, 0.06–0.24; any *KIT* exon 9: HR 0.16, 95% CI, 0.05–0.51; any *KIT* exon 13: HR 0.14, 95% CI, 0.06–0.34; any *KIT* exon 17: HR 0.14, 95% CI, 0.07–0.29; **Fig. 4**).

Common secondary mutations detected in patients with a *KIT* exon 11 primary mutation were in exon 13, exon 17, or both exons 13 and 17.




Figure 2.

KIT mutations detected outside of exons 9/11. Each circle represents 1 patient and the letter within each circle represents the amino-acid mutation location. Lettered circle indicates the protein change that occurred; nonlettered circle indicates an in-frame deletion. There were 3 patients with exon 13–only mutations, 1 patient with an exon 17–only mutation, 1 patient with exon 13 and exon 17 mutations, and 1 patient with exon 13, exon 14, and exon 17 mutations detected in liquid biopsies.

The most common secondary mutation detected in patients with a *KIT* exon 9 primary mutation was in exon 17. The calculated HRs across all of the assessed secondary subgroups within the *KIT* exon 11 or 9 subgroups favored ripretinib versus placebo (Fig. 5). Patients were categorized as *KIT*/*PDGFRA* WT if they had no detectable *KIT* or *PDGFRA* mutation in tissue biopsy, while patients with no *KIT* or *PDGFRA* mutations detected with liquid biopsy were categorized as *KIT*/*PDGFRA* liquid biopsy negative. Patients with *KIT*/*PDGFRA* WT receiving ripretinib ($n = 7$) had varying genetic alterations detected in tumor tissue, including *SDHA* and *SDHC*, *NF1*, and *KRAS* mutations, and other pathogenic alterations, such as myeloid cell leukemia 1 (*MCL1*) amplification. Two of the 7 patients had no alterations identified. Patients with *KIT*/*PDGFRA* WT on the ripretinib arm had PFS measurements that ranged from 2 to 23 months (Supplementary Table S1). Among the 10 patients with *KIT*/*PDGFRA* WT, 8 were also *KIT*/*PDGFRA* liquid biopsy negative. Of the 2 remaining patients that were considered *KIT*/*PDGFRA* WT but not *KIT*/*PDGFRA* liquid biopsy negative, liquid biopsy genotyping failed in 1 patient and an exon 13 mutation was detected in the other patient.

Discussion

The current study is the first genomic characterization of baseline mutations using tissue and liquid biopsy in patients with advanced GIST with disease progression following imatinib, sunitinib, and regorafenib treatment. This study provides a comprehensive genomic landscape of resistance mutations in a \geq fourth-line treatment setting in metastatic GIST. In this exploratory analysis, ripretinib demon-

strated clinically meaningful activity against a broad spectrum of mutations in patients with \geq fourth-line advanced GIST, with a heterogeneous genetic mutation profile as shown by the PFS benefit of ripretinib compared with placebo independent of mutation status. Patients receiving ripretinib who had tumors with any *KIT* exon 9, 11, 13, or 17 mutations showed significant PFS benefit compared with patients with these mutations receiving placebo.

In this analysis, we observed a complex and heterogeneous mutational landscape, which highlights the need for therapies that are effective against a broad spectrum of mutations. The earlier lines of approved therapy for patients with GIST inhibit certain mutations in *KIT* and *PDGFRA*, but do not inhibit all secondary mutations (23–27). Imatinib demonstrated efficacy against different primary mutations including some of the most common mutations, such as *KIT* exon 11 and *KIT* exon 9, and showed variable efficacy with *PDGFRA* exon 18 mutations (non-D842V; refs. 11, 35, 36). Imatinib shows reduced efficacy against some primary and many acquired mutations, with secondary mutations in *KIT* exon 17 and exon 13 being more frequently associated with treatment resistance and *KIT* exon 9 mutations requiring higher doses of imatinib to achieve optimal PFS (24, 26, 37). In patients receiving sunitinib, mPFS was significantly longer in patients with *KIT* exon 9 mutations compared with *KIT* exon 11 mutations (38). Additionally, patients with secondary mutations in *KIT* exon 13/14 had better outcomes on sunitinib compared with patients with mutations in *KIT* exon 17/18 (24). In contrast, third-line treatment with regorafenib demonstrated clinical benefit in patients with secondary *KIT* exon 17 mutated tumors (39). This clinical observation has been recapitulated using a mutagenesis-screen that showed complementary activity of




Figure 3. Kaplan-Meier curves of PFS by any exon 9, 11, 13, or 17. Patients may be included in multiple subgroups if they had multiple mutations. Due to low numbers, patients with any *KIT* exon 14 ($n = 6$), any *KIT* exon 18 ($n = 6$), or *PDGFRA* ($n = 3$) mutations were not analyzed.

sunitinib and regorafenib, with neither of them inhibiting mutations affecting *KIT* exon 17/18 codon D816 (23).


In the current study, when compared with placebo, ripretinib demonstrated improved efficacy in heavily pretreated patients with tumors harboring *KIT* exon 9 and exon 11 mutations. While the numbers were small, ripretinib was also more effective than placebo in patients in whom mutations in *KIT* exon 13 or *KIT* exon 17 were found. This finding is highly suggestive of the broad clinical activity of ripretinib, based on its different binding mode and activity against both activation loop and switch pocket mutations, which are associated with variable efficacy for other TKIs (24). It is important to emphasize, however, that treatment efficacy cannot be predicted solely on the presence of secondary mutations and it is not clear that ripretinib is equally potent against every resistance mutation. Both the number and allelic frequencies of different resistance mutations in liquid biopsies may not be representative of the actual distribution in all tumor cells. In addition, various genetic alterations in patients with *KIT*/*PDGFRA* WT were detected, including *SDHA*, *SDHC*, *NF-1*, *KRAS*, and *MCL1*. In particular, some cases of *SDH*-mutant GIST exhibit a slower, indolent growth (8). Disease stabilization as measured by mRECIST may represent the natural course of the disease in patients with *KIT*/*PDGFRA* WT and thus explain the PFS of 10 months

in a patient in the placebo arm with genetic alterations in *SDHA*/*TP53*. Consequently, activity of ripretinib in patients with *KIT*/*PDGFRA* WT cannot be concluded from our series and will require further study with more patients. Nonetheless, our findings using state-of-the-art NGS plasma sequencing in fourth-line GIST demonstrated no evidence of secondary resistance *KIT* mutations that would preclude clinical benefit with ripretinib treatment.

This study utilized two different technologies in order to characterize mutational status: genetic analysis based on traditional tumor tissue biopsy and liquid plasma ctDNA biopsy. The combination of these two technologies revealed a greater range of *KIT* mutations in tumors of heavily pretreated patients with GIST. There are, however, pros and cons to both tissue and liquid-biopsy methodology. Tissue biopsy is still considered the traditional gold standard methodology in clinical practice, while liquid biopsy is most commonly utilized for research purposes in sarcomas including GIST (30, 40). Archival tumor tissue is not always available and can be time consuming to retrieve. Not all tumors can be easily and safely biopsied. Moreover, although tissue biopsy is associated with high sensitivity and specificity, sampled tissue collected may not always reflect the overall frequency and spectrum of intra- and interlesional resistance mutations (40).

Figure 4.

Forest plot of HRs of PFS by any *KIT* exon 9, 11, 13, or 17. Patients may be included in multiple subgroups if they had multiple mutations. Due to low numbers, patients with any *KIT* exon 14 ($n = 6$), any *KIT* exon 18 ($n = 6$), or *PDGFRA* ($n = 3$) mutations were excluded from this analysis. ^a1 patient had both *KIT* exon 11 and *KIT* exon 9 mutations detected in liquid biopsy. QD, once daily.



Liquid biopsy is noninvasive and represents minimal burden to the patient. While tissue biopsy may be limited to easily accessible tumor tissue, and potential low tumor content due to necrosis, liquid biopsy has the potential to detect ctDNA from all tumors that shed into the circulation, potentially providing more information regarding tumor heterogeneity. However, low tumor shedding can result in a high false-negative rate in this type of biopsy (30, 40). Conversely, there may be a risk of false-positive findings when combining the two biopsy methods. In the context of resistance mutations in GIST, however, only a few hotspots are relevant in *KIT*.

In addition, it is unclear how observed mutation allele frequency relates to the underlying clone size in the patient and whether the most frequent resistance mutations found by liquid biopsy reflect the most common mutation in terms of tumor mass. In the NAVIGATOR trial, ctDNA detection correlated with the sum of the target lesions (41). In this study, however, we did not attempt to correlate ctDNA detection with tumor burden because tumor measurement per mRECIST is not equivalent to total tumor burden. Consequently, the use of both traditional tumor biopsy and liquid biopsy demonstrated the heterogeneity of *KIT* mutations in individual patients, which may not always be captured when using only one modality of tumor genomic analysis.

Additional limitations of this exploratory analysis include that patients were not randomized according to the mutational status of *KIT*/*PDGFRA* genes, and the small sample sizes did not allow for full efficacy evaluations of *KIT* exon 14 mutations, *KIT* exon 18 muta-

tions, *KIT*/*PDGFRA* WT, or *PDGFRA* mutations (particularly the exon 18 D842V substitution mutation). However, the rationale for this study design was to provide patients with \geq fourth-line advanced GIST effective treatment, since the median PFS for patients with untreated GIST after failing several TKIs is approximately 1 month (42, 43). While the grouping for the efficacy analysis (*KIT* exons 9, 11, 13, and 17) was driven by sample size, these are common primary and secondary mutations in GIST, and efficacy against these mutations support ripretinib's broad mechanism of action (24, 26). Longitudinal liquid biopsy analysis is ongoing and will add valuable information to the complexity of mutational status while patients are on treatment. In addition, previous studies have also identified *KIT*- and *PDGFRA*-independent mechanisms of resistance, such as mutations in PI3K, TSC1, MAPK, RAF, and RAS (7, 44). These may represent escape mechanisms that could also potentiate mechanisms of resistance to ripretinib, regardless of effective *KIT*/*PDGFRA* inhibition.

In conclusion, patients from the INVICTUS study exhibited complex and heterogeneous mutational backgrounds as determined by both tissue and liquid biopsy. Despite some limitations with liquid biopsy results, this screening technique provides a novel and noninvasive investigational tool with potential high clinical utility to determine patients' genotype. This analysis demonstrates that ripretinib provided clinically meaningful benefit across mutation subgroups when compared with placebo. These results support the use of ripretinib as a fourth-line therapy in patients with advanced GIST harboring a broad spectrum of mutations.




Figure 5.

Forest plot of hazard ratios of PFS within any *KIT* exons 9 or 11. ^aOne patient had both a *KIT* exon 11 mutation and a *KIT* exon 9 mutation detected in liquid biopsy. ^bIncludes exon 11-only mutations ($n = 13$) and exon 11 + 18 mutations ($n = 1$).

Authors' Disclosures

S. Bauer reports personal fees from Deciphera Pharmaceuticals, Roche, Exelixis, Plexxikon, and Daiichi Sankyo; grants from Incyte; grants and personal fees from Blueprint Medicines and Novartis; personal fees and other support from Bayer and Pharmamar; and other support from Pfizer during the conduct of the study. S. Bauer also reports personal fees from GSK outside the submitted work. M.C. Heinrich reports personal fees from Deciphera Pharmaceuticals, Theseus, and Blueprint Medicines during the conduct of the study. M.C. Heinrich also reports personal fees and other support from MolecularMD, as well as personal fees from Novartis outside the submitted work; in addition, M.C. Heinrich has a patent for Imatinib treatment of GIST issued, licensed, and with royalties paid from Novartis. S. George reports other support from Abbott Laboratories, Kayothera, Daiichi Sankyo, Springworks, UpToDate, ResearchToPractice, MORE Health, Grand Rounds, and NCCN; personal fees and other support from Deciphera Pharmaceuticals and Blueprint Medicines; personal fees from Eli Lilly; and grants and other support from Eisai and Merck outside the submitted work. In addition, S. George is the Vice Chair Alliance for Clinical Trials in Oncology and Vice President of Alliance Foundation. J.R. Zalberg reports other support from Deciphera Pharmaceuticals during the conduct of the study; J.R. Zalberg also reports grants from MSD, as well as personal fees from MSD, STA, Merck, Targovax, Halozyme, CEND, and Gilead outside the submitted work. In addition, J.R. Zalberg owns stock in GW Pharmaceuticals, Aimmune, Vertex, Alnylam, Biomarin, Opthea, Armarin, Concert Pharmaceuticals, Frequency Therapeutics, Global Blood Therapeutics, Gilead, Madrigal Pharmaceuticals, Sangamo Biosciences, Acceleron Pharmaceuticals, Zogenix, Myovant Sciences, Orphazyme, Moderna Therapeutics, Novo Nordisk, Novavax, and TWST. C. Serrano reports grants and personal fees from Deciphera Pharmaceuticals; grants and non-financial support from Pfizer and Bayer; personal fees and non-financial support from Blueprint; personal fees from Immunicum; and non-financial support from Novartis,

Lilly, and Pharmamar during the conduct of the study. H. Gelderblom reports institutional funding from Daiichi Sankyo, Novartis, Deciphera Pharmaceuticals, Debio, and Boehringer Ingelheim. R.L. Jones reports other support from Deciphera Pharmaceuticals during the conduct of the study, as well as personal fees from Athenex, Eisai, Blueprint, Deciphera Pharmaceuticals, Pharmamar, Tracoon, Springworks, and UpToDate outside the submitted work; in addition, R.L. Jones has a patent for Biomarker pending. S. Attia reports grants from Deciphera Pharmaceuticals during the conduct of the study, as well as grants from AB Science, Tracoon, GSK, BTG, Bayer, Novartis, Lilly, Immune Design, Karyopharm, Epizyme, Blueprint, Genmab, CBA, DTRF, Merck, Philogen, Gradilis, Takeda, Incyte, Springworks, Adaptimmune, Advenchen, PTC Therapeutics, Bavarian Nordic, and FORMA Therapeutics outside the submitted work. G. D'Amato reports other support from Deciphera Pharmaceuticals, Blueprint, Daiichi Sankyo, and Epizyme outside the submitted work. P. Chi reports grants, personal fees and non-financial support from Deciphera Pharmaceuticals during the conduct of the study; P. Chi also reports personal fees from Exelixis and Zai Lab, as well as grants from NingboNewBay and Pfizer outside the submitted work. P. Reichardt reports personal fees from Bayer, Clinigen, BMS, Roche, MSD, Deciphera Pharmaceuticals, Novartis, Pfizer, Pharmamar, Lilly, Amgen, and Blueprint outside the submitted work. J. Meade reports personal fees from Deciphera Pharmaceuticals during the conduct of the study, as well as other support from Deciphera Pharmaceuticals outside the submitted work; in addition, J. Meade is an employee of Deciphera Pharmaceuticals. Y. Su reports employment at Deciphera Pharmaceuticals. R. Ruiz-Soto reports other support from Deciphera Pharmaceuticals during the conduct of the study, as well as other support from Deciphera Pharmaceuticals outside the submitted work. J.-Y. Blay reports grants from Deciphera Pharmaceuticals during the conduct of the study; J.-Y. Blay also reports grants and personal fees from Deciphera Pharmaceuticals, Blueprint, and Eisai, as well as grants from Bayer outside the submitted work. M. von Mehren reports personal fees and other support from Deciphera Pharmaceuticals, as well as personal fees from

Blueprint Medicines and Exelixis outside the submitted work. P. Schöffski reports personal fees from Deciphera Pharmaceuticals during the conduct of the study; P. Schöffski also reports personal fees from Blueprint Medicines, Boehringer Ingelheim, Ellipses Pharma, Transgene, Exelixis, Medscape, Guided Clarity, Ysios Capital, and Curio Science, as well as other support from Blueprint Medicines, Ellipses Pharma, Adaptimmune, Intellisphere, Transgene, and Advance Medical outside the submitted work. No disclosures were reported by the other authors.

Authors' Contributions

S. Bauer: Conceptualization, resources, supervision, investigation, writing—original draft, writing—review and editing. **M.C. Heinrich:** Conceptualization, resources, supervision, investigation, writing—original draft, writing—review and editing. **S. George:** Resources, supervision, investigation, writing—review and editing. **J.R. Zalberg:** Resources, supervision, investigation, writing—review and editing. **C. Serrano:** Resources, supervision, investigation, writing—review and editing. **H. Gelderblom:** Resources, supervision, investigation, writing—review and editing. **R.L. Jones:** Resources, supervision, investigation, writing—review and editing. **S. Attia:** Resources, supervision, investigation, writing—review and editing. **G. D'Amato:** Resources, supervision, investigation, writing—review and editing. **P. Chi:** Resources, supervision, investigation, writing—review and editing. **P. Reichardt:** Resources, supervision, investigation, writing—review and editing. **J. Meade:** Conceptualization, visualization, writing—original

draft, project administration, writing—review and editing. **Y. Su:** Conceptualization, formal analysis, visualization, writing—original draft, project administration, writing—review and editing. **R. Ruiz-Soto:** Conceptualization, visualization, writing—original draft, project administration, writing—review and editing. **J.-Y. Blay:** Resources, supervision, investigation, writing—review and editing. **M. von Mehren:** Resources, supervision, investigation, writing—review and editing. **P. Schöffski:** Conceptualization, resources, supervision, investigation, writing—original draft, writing—review and editing.

Acknowledgments

This study was sponsored by Deciphera Pharmaceuticals, LLC.

Medical writing and editorial support were provided by Lauren Hanlon, PhD, of AlphaBioCom, LLC, King of Prussia, Pennsylvania. This support was funded by Deciphera Pharmaceuticals, LLC.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 4, 2021; revised August 4, 2021; accepted September 7, 2021; published first September 9, 2021.

References

- Patel N, Benipal B. Incidence of gastrointestinal stromal tumors in the United States from 2001–2015: a United States cancer statistics analysis of 50 states. *Cureus* 2019;11:e4120.
- Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. *Lancet* 2007;369:1731–41.
- Soreide K, Sandvik OM, Soreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. *Cancer Epidemiol* 2016;40:39–46.
- Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. *PDGFRA* mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. *J Clin Oncol* 2005;23:5357–64.
- Martin-Broto J, Martinez-Marin V, Serrano C, Hindi N, Lopez-Guerrero JA, Bisculosa M, et al. Gastrointestinal stromal tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis. *Clin Transl Oncol* 2017;19:536–45.
- Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. *Future Oncol* 2017;13:93–107.
- Mühlenberg T, Ketzler J, Heinrich MC, Grunewald S, Marino-Enriquez A, Trautmann M, et al. *KIT*-dependent and *KIT*-independent genomic heterogeneity of resistance in gastrointestinal stromal tumors - *TORC1/2* inhibition as salvage strategy. *Mol Cancer Ther* 2019;18:1985–96.
- Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, et al. Molecular subtypes of *KIT*/*PDGFRA* wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health gastrointestinal stromal tumor clinic. *JAMA Oncol* 2016;2:922–8.
- Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant *KIT* and *PDGFRA* variants. *Cancer Cell* 2019;35:738–51e9.
- Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. *J Biol Chem* 2004;279:31655–63.
- Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. *J Clin Oncol* 2004;22:3813–25.
- Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science* 1998;279:577–80.
- Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. *KIT* activation is a ubiquitous feature of gastrointestinal stromal tumors. *Cancer Res* 2001;61:8118–21.
- Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. *PDGFRA* activating mutations in gastrointestinal stromal tumors. *Science* 2003;299:708–10.
- Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. *Hum Pathol* 2002;33:466–77.
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines) soft tissue sarcoma 2020; Version 1.2021.
- Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. *Chemother Res Pract* 2014;2014:357027.
- Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. *Ann Oncol* 2007;18 Suppl 10:x3–10.
- Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, et al. Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical anti-tumor activity. *Int J Cancer* 2011;129:245–55.
- Blueprint Medicines. Ayvakit. Prescribing information. Cambridge (MA): Blueprint Medicines Corporation; 2020. Reference ID: 4544122. Available from: <https://www.blueprintmedicines.com/uspi/AYYAKIT.pdf>.
- Gebreyohannes YK, Wozniak A, Zhai ME, Wellens J, Cornillie J, Vanleeuw U, et al. Robust activity of avapritinib, potent and highly selective inhibitor of mutated *KIT*, in patient-derived xenograft models of gastrointestinal stromal tumors. *Clin Cancer Res* 2019;25:609–18.
- Li K, Cheng H, Li Z, Pang Y, Jia X, Xie F, et al. Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions. *Oncotarget* 2017;8:60589–604.
- Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, et al. Ponatinib inhibits polyclonal drug-resistant *KIT* oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. *Clin Cancer Res* 2014;20:5745–55.
- Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. *J Clin Oncol* 2008;26:5352–9.
- Serrano C, Marino-Enriquez A, Tao DL, Ketzler J, Eilers G, Zhu M, et al. Complementary activity of tyrosine kinase inhibitors against secondary *kit* mutations in imatinib-resistant gastrointestinal stromal tumours. *Br J Cancer* 2019;120:612–20.
- Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. *Clin Cancer Res* 2005;11:4182–90.
- Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Büttner R, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple *KIT* mutations. *Lancet Oncol* 2005;6:249–51.
- Qinlock. Prescribing information. Waltham (MA): Deciphera Pharmaceuticals, LLC; 2020. [updated 2020 May]. Available from: <https://qinlockhcp.com/Content/files/qinlock-prescribing-information.pdf>.
- Blay JY, Serrano C, Heinrich MC, Zalberg J, Bauer S, Gelderblom H, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* 2020;21:923–34.

30. Nannini M, Astolfi A, Urbini M, Biasco G, Pantaleo MA. Liquid biopsy in gastrointestinal stromal tumors: a novel approach. *J Transl Med* 2014;12:210.
31. Ravegnini G, Sammarini G, Serrano C, Nannini M, Pantaleo MA, Hrelia P, et al. Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors. *Ther Adv Med Oncol* 2019;11:1758835919831902.
32. Gómez-Peregrina D, García-Valverde A, Pilco-Janeta D, Serrano C. Liquid biopsy in gastrointestinal stromal tumors: ready for prime time? *Curr Treat Options Oncol* 2021;22:32.
33. FoundationOne CDx Technical Information. Cambridge, MA: Foundation Medicine, Inc.; 2020. Reference ID: RAL-0003-10. Available from: https://info.foundationmedicine.com/hubfs/FMI%20Labels/FoundationOne_CDx_Label_Technical_Info.pdf.
34. Guardant360 CDx Technical Information. Redwood City (CA): Guardant Health, Inc.; 2020. Reference ID: D-000352 R1. Available from: <https://guardant360cdx.com/wp-content/uploads/2021/06/D-001590-Guardant360-CDx-Technical-Information-Document-R1.pdf>.
35. Chen P, Zong L, Zhao W, Shi L. Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis. *World J Gastroenterol* 2010;16:4227-32.
36. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. *J Clin Oncol* 2006;24:4764-74.
37. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. *Eur J Cancer* 2006;42:1093-103.
38. Reichardt P, Demetri GD, Gelderblom H, Rutkowski P, Im SA, Gupta S, et al. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a world-wide treatment-use trial. *BMC Cancer* 2016;16:22.
39. Yeh CN, Chen MH, Chen YY, Yang CY, Yen CC, Tzen CY, et al. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. *Oncotarget* 2017;8:44121-30.
40. Diaz LA Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. *J Clin Oncol* 2014;32:579-86.
41. Grunewald S, Klug LR, Muhlenberg T, Lategahn J, Falkenhörst J, Town A, et al. Resistance to avapritinib in PDGFRA-Driven GIST is caused by secondary mutations in the PDGFRA kinase domain. *Cancer Discov* 2021;11:108-25.
42. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013;381:295-302.
43. Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* 2013;14:1175-82.
44. Serrano C, Wang Y, Mariño-Enríquez A, Lee JC, Ravegnini G, Morgan JA, et al. KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation. *J Clin Oncol* 2015;33:e93-6.